These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 29500455)

  • 1. Trichostatin A reverses the chemoresistance of lung cancer with high IGFBP2 expression through enhancing autophagy.
    Tang D; Yao R; Zhao D; Zhou L; Wu Y; Yang Y; Sun Y; Lu L; Gao W
    Sci Rep; 2018 Mar; 8(1):3917. PubMed ID: 29500455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance.
    Dong X; Lin D; Low C; Vucic EA; English JC; Yee J; Murray N; Lam WL; Ling V; Lam S; Gout PW; Wang Y
    J Thorac Oncol; 2013 Feb; 8(2):161-70. PubMed ID: 23287853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of special AT-rich binding protein 1 expression is a marker of poor survival in lung cancer.
    Selinger CI; Cooper WA; Al-Sohaily S; Mladenova DN; Pangon L; Kennedy CW; McCaughan BC; Stirzaker C; Kohonen-Corish MR
    J Thorac Oncol; 2011 Jul; 6(7):1179-89. PubMed ID: 21597389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IGFBP2/FAK pathway is causally associated with dasatinib resistance in non-small cell lung cancer cells.
    Lu H; Wang L; Gao W; Meng J; Dai B; Wu S; Minna J; Roth JA; Hofstetter WL; Swisher SG; Fang B
    Mol Cancer Ther; 2013 Dec; 12(12):2864-73. PubMed ID: 24130049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insulin-like growth factor binding protein-2 level is increased in blood of lung cancer patients and associated with poor survival.
    Guo C; Lu H; Gao W; Wang L; Lu K; Wu S; Pataer A; Huang M; El-Zein R; Lin T; Roth JA; Mehran R; Hofstetter W; Swisher SG; Wu X; Fang B
    PLoS One; 2013; 8(9):e74973. PubMed ID: 24069370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyperglycaemia-induced chemoresistance of prostate cancer cells due to IGFBP2.
    Biernacka KM; Uzoh CC; Zeng L; Persad RA; Bahl A; Gillatt D; Perks CM; Holly JM
    Endocr Relat Cancer; 2013 Oct; 20(5):741-51. PubMed ID: 23959956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is insulin-like growth factor binding protein 2 associated with metastasis in lung cancer?
    Hu Q; Huang L; Kuang X; Zhang H; Ling G; Chen X; Li K; Deng Z; Zhou J
    Clin Exp Metastasis; 2014 Jun; 31(5):535-41. PubMed ID: 24682597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CXCR4 promotes cisplatin-resistance of non-small cell lung cancer in a CYP1B1-dependent manner.
    Xie S; Tu Z; Xiong J; Kang G; Zhao L; Hu W; Tan H; Tembo KM; Ding Q; Deng X; Huang J; Zhang Q
    Oncol Rep; 2017 Feb; 37(2):921-928. PubMed ID: 27922681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expressions of insulin-like growth factor receptor-1 and insulin-like growth factor binding protein 3 in advanced non-small-cell lung cancer.
    Kim YH; Sumiyoshi S; Hashimoto S; Masago K; Togashi Y; Sakamori Y; Okuda C; Mio T; Mishima M
    Clin Lung Cancer; 2012 Sep; 13(5):385-90. PubMed ID: 22285568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IGFBP2 modulates the chemoresistant phenotype in esophageal adenocarcinoma.
    Myers AL; Lin L; Nancarrow DJ; Wang Z; Ferrer-Torres D; Thomas DG; Orringer MB; Lin J; Reddy RM; Beer DG; Chang AC
    Oncotarget; 2015 Sep; 6(28):25897-916. PubMed ID: 26317790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of insulin-like growth factor receptor signaling mediates resistance to histone deacetylase inhibitors.
    Kim JS; Lee SC; Min HY; Park KH; Hyun SY; Kwon SJ; Choi SP; Kim WY; Lee HJ; Lee HY
    Cancer Lett; 2015 Jun; 361(2):197-206. PubMed ID: 25721083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CMTM1_v17 is associated with chemotherapy resistance and poor prognosis in non-small cell lung cancer.
    Si J; Zhang P; Tian D; Wang X; Ma Y; Zhang J; Wang L; Yang Y
    World J Surg Oncol; 2017 Jan; 15(1):34. PubMed ID: 28129775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancement of tumor initiation and expression of KCNMA1, MORF4L2 and ASPM genes in the adenocarcinoma of lung xenograft after vorinostat treatment.
    Kuo WY; Wu CY; Hwu L; Lee JS; Tsai CH; Lin KP; Wang HE; Chou TY; Tsai CM; Gelovani J; Liu RS
    Oncotarget; 2015 Apr; 6(11):8663-75. PubMed ID: 25796627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum IGFBP2 Level Is a New Candidate Biomarker of Severe Malnutrition in Advanced Lung Cancer.
    Dong J; Zeng Y; Zhang P; Li C; Chen Y; Li Y; Wang K
    Nutr Cancer; 2020; 72(5):858-863. PubMed ID: 32286106
    [No Abstract]   [Full Text] [Related]  

  • 15. Prognostic value of E-cadherin expression in non-small cell lung cancer treated with gefitinib.
    Kook EH; Kim YM; Kim HT; Koh JS; Choi YJ; Rho JK; Kim HR; Kim CH; Lee JC
    Oncol Res; 2010; 18(9):445-51. PubMed ID: 20524402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of TAZ expression in resected non-small cell lung cancer.
    Xie M; Zhang L; He CS; Hou JH; Lin SX; Hu ZH; Xu F; Zhao HY
    J Thorac Oncol; 2012 May; 7(5):799-807. PubMed ID: 22481233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance of insulin-like growth factor-binding protein-3 expression in stage I non-small cell lung cancer.
    Chang YS; Kong G; Sun S; Liu D; El-Naggar AK; Khuri FR; Hong WK; Lee HY
    Clin Cancer Res; 2002 Dec; 8(12):3796-802. PubMed ID: 12473592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sensitization to gamma-irradiation-induced cell cycle arrest and apoptosis by the histone deacetylase inhibitor trichostatin A in non-small cell lung cancer (NSCLC) cells.
    Zhang F; Zhang T; Teng ZH; Zhang R; Wang JB; Mei QB
    Cancer Biol Ther; 2009 May; 8(9):823-31. PubMed ID: 19270532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined Pan-HER and ALK/ROS1/MET Inhibition with Dacomitinib and Crizotinib in Advanced Non-Small Cell Lung Cancer: Results of a Phase I Study.
    Jänne PA; Shaw AT; Camidge DR; Giaccone G; Shreeve SM; Tang Y; Goldberg Z; Martini JF; Xu H; James LP; Solomon BJ
    J Thorac Oncol; 2016 May; 11(5):737-747. PubMed ID: 26899759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in programmed death ligand 1 expression in non-small cell lung cancer patients who received anticancer treatments.
    Omori S; Kenmotsu H; Abe M; Watanabe R; Sugino T; Kobayashi H; Nakashima K; Wakuda K; Ono A; Taira T; Naito T; Murakami H; Ohde Y; Endo M; Akiyama Y; Nakajima T; Takahashi T
    Int J Clin Oncol; 2018 Dec; 23(6):1052-1059. PubMed ID: 29948239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.